Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
18. Juni 2020 07:57 ET
|
Aptinyx Inc.
EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
14. Mai 2020 16:03 ET
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
30. April 2020 08:47 ET
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30. März 2020 16:01 ET
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
18. März 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
19. Februar 2020 08:37 ET
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
30. Januar 2020 07:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
14. Januar 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
05. Dezember 2019 06:58 ET
|
Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
Aptinyx to Present at Upcoming Investor Conferences
14. November 2019 07:57 ET
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...